ES2162913T3 - Preparado farmaceutico que contiene activadores de plasminogeno. - Google Patents

Preparado farmaceutico que contiene activadores de plasminogeno.

Info

Publication number
ES2162913T3
ES2162913T3 ES95910500T ES95910500T ES2162913T3 ES 2162913 T3 ES2162913 T3 ES 2162913T3 ES 95910500 T ES95910500 T ES 95910500T ES 95910500 T ES95910500 T ES 95910500T ES 2162913 T3 ES2162913 T3 ES 2162913T3
Authority
ES
Spain
Prior art keywords
pharmaceutical preparation
preparation containing
plasminogen activators
containing plasminogen
sugar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95910500T
Other languages
English (en)
Inventor
Ulrich Kohnert
Stephan Fischer
Hans-Jorg Markl
Heinrich Woog
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Application granted granted Critical
Publication of ES2162913T3 publication Critical patent/ES2162913T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION TRATA DE PREPARADOS FARMACEUTICOS QUE CONTIENEN ACTIVADORES DEL PLASMINOGENO, AZUCAR Y ACIDO TRANEXAMICO COMO UN LIOFILIZADO O UNA SOLUCION PARA INYECTAR O INFUNDIR. LOS PREPARADOS CONTIENEN EN PARTICULAR UN AZUCAR, UN AMORTIGUADOR DE FOSFATO, ACIDO TRANEXAMICO Y UN TENSIOACTIVO, Y LAS SOLUCIONES LIQUIDAS TIENEN PREFERIBLEMENTE UN PH DE 5,5-6,5.
ES95910500T 1994-02-21 1995-02-18 Preparado farmaceutico que contiene activadores de plasminogeno. Expired - Lifetime ES2162913T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4405426A DE4405426A1 (de) 1994-02-21 1994-02-21 Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate

Publications (1)

Publication Number Publication Date
ES2162913T3 true ES2162913T3 (es) 2002-01-16

Family

ID=6510724

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95910500T Expired - Lifetime ES2162913T3 (es) 1994-02-21 1995-02-18 Preparado farmaceutico que contiene activadores de plasminogeno.

Country Status (26)

Country Link
US (1) US5747030A (es)
EP (1) EP0746334B1 (es)
JP (1) JP3868997B2 (es)
KR (1) KR100356934B1 (es)
CN (1) CN1170591C (es)
AT (1) ATE205091T1 (es)
AU (1) AU691881B2 (es)
BR (1) BR9506840A (es)
CA (1) CA2183755C (es)
CZ (1) CZ286682B6 (es)
DE (2) DE4405426A1 (es)
DK (1) DK0746334T3 (es)
ES (1) ES2162913T3 (es)
FI (1) FI117925B (es)
HU (1) HU219769B (es)
MX (1) MX9603515A (es)
NO (1) NO317726B1 (es)
NZ (1) NZ281607A (es)
PL (1) PL181257B1 (es)
PT (1) PT746334E (es)
RU (1) RU2155067C2 (es)
SG (1) SG50567A1 (es)
SK (1) SK282827B6 (es)
TW (1) TW337997B (es)
WO (1) WO1995022347A1 (es)
ZA (1) ZA951371B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
US6653062B1 (en) * 2000-07-26 2003-11-25 Wisconsin Alumni Research Foundation Preservation and storage medium for biological materials
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US20090214644A1 (en) * 2003-07-31 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations with reduced adverse effects
US20050245614A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20050244495A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US8022106B2 (en) * 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
TW200738261A (en) 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
EA202092926A3 (ru) 2014-03-24 2021-10-29 Биовератив Терапьютикс Инк. Лиофилизированные составы, содержащие фактор ix
US11666532B2 (en) * 2018-01-19 2023-06-06 Hyloris Developments Sa Tranexamic acid oral solution
US10980757B2 (en) 2018-09-06 2021-04-20 RTU Pharma SA Ready-to-use tranexamic acid intravenous solution
CN116033931A (zh) * 2020-08-10 2023-04-28 奇斯药制品公司 组织纤溶酶原激活剂制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3718889A1 (de) * 1987-06-05 1988-12-22 Behringwerke Ag Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung
DE3942144A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von k1k2p pro

Also Published As

Publication number Publication date
DE59509580D1 (de) 2001-10-11
EP0746334B1 (de) 2001-09-05
BR9506840A (pt) 1997-10-14
DE4405426A1 (de) 1995-08-24
AU691881B2 (en) 1998-05-28
KR970701059A (ko) 1997-03-17
CN1170591C (zh) 2004-10-13
TW337997B (en) 1998-08-11
HU219769B (hu) 2001-07-30
PT746334E (pt) 2002-02-28
FI963251A0 (fi) 1996-08-20
CA2183755A1 (en) 1995-08-24
MX9603515A (es) 1997-03-29
HUT74843A (en) 1997-02-28
KR100356934B1 (ko) 2003-02-26
NO963460D0 (no) 1996-08-20
ZA951371B (en) 1996-08-20
HU9602284D0 (en) 1996-10-28
JP3868997B2 (ja) 2007-01-17
CN1141592A (zh) 1997-01-29
NO963460L (no) 1996-10-18
NZ281607A (en) 1997-04-24
WO1995022347A1 (de) 1995-08-24
DK0746334T3 (da) 2001-12-27
PL315978A1 (en) 1996-12-23
ATE205091T1 (de) 2001-09-15
CZ243196A3 (en) 1997-01-15
US5747030A (en) 1998-05-05
EP0746334A1 (de) 1996-12-11
CA2183755C (en) 2004-02-17
RU2155067C2 (ru) 2000-08-27
AU1758195A (en) 1995-09-04
SK282827B6 (sk) 2002-12-03
SG50567A1 (en) 1998-07-20
FI117925B (fi) 2007-04-30
JPH09511495A (ja) 1997-11-18
CZ286682B6 (en) 2000-06-14
SK107996A3 (en) 1997-04-09
PL181257B1 (pl) 2001-06-29
NO317726B1 (no) 2004-12-13
FI963251L (fi) 1996-08-20

Similar Documents

Publication Publication Date Title
DE69328777D1 (de) Dekontaminierung von Plättchen mit 8-Methoxypsoralen
ES8403321A1 (es) Procedimiento para la produccion de un preparado solido de fibrinogeno.
ES2060593T3 (es) Sistema de aporte de farmacos.
DK630188D0 (da) Laegemidler med indhold af azelastin til anvendelse i naesen og/eller i oejet
ATE172359T1 (de) Kalt-sterilisermittel mit verlängerter aktivät
DK0656213T3 (da) Kombineret anvendelse af hyaluronsyre og terapeutiske aktivstoffer til forbedring af den terapeutiske effekt
ECSP034883A (es) Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que las contienen
EP0754461A3 (en) A preservation solution of blood platelets
ES2094539T3 (es) Preparacion farmaceutica y procedimiento para su preparacion.
DE10199011I1 (de) Asp-B28-Insulinkristalle
IS1565B (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
MX9603515A (es) Preparacion farmaceutica que contiene activadores de plasminogeno.
DE2742529A1 (de) Plasminogen-aktivatorkomplex, verfahren zu seiner herstellung und ihn enthaltendes arzneimittel
CO4340690A1 (es) Los derivados de la quinolonilcarboxamidocefalosporina y las composiciones farmaceuticas que las contienen
ES2169915T3 (es) Composicion utilizable en los ambitos farmaceutico, dietetico y cosmetico.
SE8501518D0 (sv) Pharmazeutische preparate
ATE4216T1 (de) 3-hydrocarbylthio-2-acyloxypropyl 2trimethylammonioethyl phosphate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen.
ES2057528T3 (es) Pdgf-a, pdgf-aa, pdgf-ab, procedimientos de preparacion y medicamentos que los contienen.
DE3579074D1 (de) Verminderung der toxischen wirkungen von anthrachinon-medikamenten.
ES2037677T3 (es) Uso de un acido carboxilico en preparados farmaceuticos destinados a aplicacion topica.
AR002001A1 (es) Solucion para administracion intravenosa de lubeluzol, procedimiento para su preparacion, una jeringa previamente llenada, un paquete para infusion parael tratamiento agudo del infarto y el uso de sustancias acidas o basicas en una solucion.
FI971098L (fi) Neulattomien painevälinekäyttöisten injektointilaitteiden käyttö vaikuttavien aineiden antamiseksi kasveille
AR002258A1 (es) Derivados de fenoxipirimidinilo, preparaciones farmaceuticas que los contienen, un procedimiento para su preparacion y su empleo para preparar medicamentos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 746334

Country of ref document: ES